Trial Profile

Phase 1b/2 clinical trial for CYTO-401 in late-stage, non-resectable pancreatic cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Methionine enkephalin (Primary)
Indications Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

23 Aug 2021 New trial record
16 Aug 2021 According to Cytocom media release, the company has completed Type C meeting and expect to initiate this trial in the first half of 2022.
16 Aug 2021 According to Cytocom media release, enrollment is expected to begin by mid-2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com